Insulin resistance in obesity can be reliably identified from fasting plasma insulin

Horst, Kasper W. ter; Gilijamse, Pim W.; Koopman, Karin E.; Weijer, Barbara A. de; Brands, M.; Kootte, Ruud S.; Romijn, Johannes A.; Ackermans, M. T.; Nieuwdorp, Max; Soeters, Maarten R.; Serlie, Mireille J.

doi:10.1038/ijo.2015.125

Cited by 60 publications

(55 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3D). Moreover, in the entire cohort of morbidly obese women, who were characterized by moderate-to-severe insulin resistance compared with healthy non-obese subjects [21], clamp-derived measurements of glucose metabolism and insulin action did not correlate with either circulating 25(OH)D or 1,25(OH) 2 D metabolites ( Fig. 4A-H).…”

Section: Vitamin D Metabolites Were Not Related To Glucose Metabolismmentioning

confidence: 76%

“…The basal rate of endogenous glucose production (EGP), insulin-mediated suppression of EGP (hepatic insulin sensitivity), insulin-mediated suppression of circulating free fatty acids (FFA; adipose-tissue insulin sensitivity) and insulin-stimulated rate of disappearance (Rd) of glucose (peripheral/muscle insulin sensitivity) were assessed during a two-step euglycaemic-hyperinsulinaemic clamp study, described in detail elsewhere [21]. In brief, subjects were admitted to the metabolic unit after an overnight fast.…”

Section: Experimental Protocolmentioning

confidence: 99%

See 1 more Smart Citation

The vitamin D metabolites 25(OH)D and 1,25(OH)2D are not related to either glucose metabolism or insulin action in obese women

Horst

Versteeg

Gilijamse

et al. 2016

Diabetes & Metabolism

View full text Add to dashboard Cite

Section: Vitamin D Metabolites Were Not Related To Glucose Metabolismmentioning

confidence: 76%

Section: Experimental Protocolmentioning

confidence: 99%

The vitamin D metabolites 25(OH)D and 1,25(OH)2D are not related to either glucose metabolism or insulin action in obese women

Horst

Versteeg

Gilijamse

et al. 2016

Diabetes & Metabolism

View full text Add to dashboard Cite

“…Concerning a possible association between insulin resistance and basal hyperinsulinaemia in HA children, it is unlikely in this study, as S I is slightly lower in HA than in EA children ( P = 0.04) (Table 1). In fact, obese children tended to be less insulin sensitive, 22 and even if HA children had the highest obesity rates (see Results), the S I impairment is lost when adjusting for percentage of body fat (Table 1). …”

Section: Discussionmentioning

confidence: 87%

Dissection of hepatic versus extra‐hepatic insulin clearance: Ethnic differences in childhood

Piccinini

Polidori

Gower

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Furthermore, there was a significant decrease in fasting insulin levels (25% reduction) in mice treated with the 1 µg dose of IL-37 (Fig. 1f), in support of improved insulin sensitivity (27).…”

Section: Treatment With Recombinant Il-37 Reverses Impaired Insulin Smentioning

confidence: 91%

Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue

Ballak

Cavalli

et al. 2018

Journal of Biological Chemistry

View full text Add to dashboard Cite

Obesity and the metabolic syndrome are characterized by chronic, low-grade inflammation mainly originating from expanding adipose tissue and resulting in inhibition of insulin signaling and disruption of glycemic control. Transgenic mice expressing human interleukin 37 (IL-37), an anti-inflammatory cytokine of the IL-1 family, are protected against metabolic syndrome when fed a high-fat diet (HFD) containing 45% fat. Here, we examined whether treatment with recombinant IL-37 ameliorates established insulin resistance and obesity-induced inflammation. Wildtype mice were fed a HFD for 22 weeks and then treated daily with IL-37 (1 µg/mouse) during the last 2 weeks. Compared with vehicle only-treated mice, IL-37-treated mice exhibited reduced insulin in the plasma and had significant improvements in glucose tolerance, and insulin content of the islets. The IL-37 treatment also increased the levels of circulating IL-1 receptor antagonist. Cultured adipose tissues revealed that IL-37 treatment significantly decreases spontaneous secretions of IL-1β, tumor necrosis factor α (TNFα), and C-X-C motif chemokine ligand 1 (CXCL-1). We also fed mice a 60% fat diet with concomitant daily IL-37 for 2 weeks and observed decreased secretion of IL-1β, TNFα, and IL-6 and reduced intracellular levels of IL-1α in the liver and adipose tissue, along with improved plasma glucose clearance. Compared with vehicle treatment, these IL-37-treated mice had no apparent weight gain. In human adipose tissue cultures, the presence of 50 pM IL-37 reduced spontaneous release of TNFα and 50% of lipopolysaccharide-induced TNFα. These findings indicate that IL-37's antiinflammatory effects can ameliorate established metabolic disturbances during obesity.

show abstract

Insulin resistance in obesity can be reliably identified from fasting plasma insulin

Cited by 60 publications

References 44 publications

The vitamin D metabolites 25(OH)D and 1,25(OH)2D are not related to either glucose metabolism or insulin action in obese women

The vitamin D metabolites 25(OH)D and 1,25(OH)2D are not related to either glucose metabolism or insulin action in obese women

Dissection of hepatic versus extra‐hepatic insulin clearance: Ethnic differences in childhood

Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue

Contact Info

Product

Resources

About